Compare Iron Mountain Inc (IRM) vs Novavax Inc (NVAX) Price & Performance

Iron Mountain (IRM) trades at $124.67, up 2.56% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $6.90B in 2025, though net margins compressed to 2.09%. The stock is supported by a 65% analyst buy rating and a $141.50 consensus target, with institutional interest highlighted by recent purchases. Key risks include high debt levels, with a debt-to-asset ratio of 79.04% in 2025.

Outlook remains mixed; robust data center growth and dividend yield near 2.8% offer upside, but elevated valuation (P/E 86.8) and persistent negative shareholder equity warrant caution. Earnings momentum from Q2 2026 beat provides near-term support, yet debt servicing and competitive pressures pose headwinds for sustained gains.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.